Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;82(3):335-340.
doi: 10.1007/s40265-022-01677-4.

Maribavir: First Approval

Connie Kang  1
Affiliations
Review

Maribavir: First Approval

Connie Kang. Drugs. 2022 Feb.

Abstract

Maribavir (LIVTENCITYTM), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. US Food & Drug Administration. FDA approves first treatment for common type of post-transplant infection that is resistant to other drugs [media release]. 23 Nov 2021. https://www.fda.gov .
    1. Takeda Pharmaceuticals. LIVTENCITY (maribavir) tablets, for oral use: US prescribing information. 2021. https://content.takeda.com . Accessed 26 Jan 2022.
    1. ViroPharma Incorporated. ViroPharma licenses rights from GlaxoSmithKline for product candidate for cytomegalovirus (CMV) in immunocompromised patients [media release]. 11 Aug 2003. http://www.viropharma.com .
    1. Takeda. Shire successfully completes tender offer for Viropharma [media release]. 24 Jan 2014. https://takeda.com .
    1. Takeda. Takeda completes acquisition of Shire, becoming a global, values-based, R&D-driven biopharmaceutical leader [media release]. 8 Jan 2019. https://takeda.com .